Related Experiment Video

Updated: Jul 23, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers

Milad Zandi1, Maryam Shafaati2, Mohammad Shenagari3

  • 1Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Heliyon
|July 17, 2023
PubMed

Insights

CD47, an immune checkpoint protein, is overexpressed on cancer and SARS-CoV-2 infected cells. Targeting the CD47-SIRPα pathway offers a novel immunotherapy strategy for COVID-19 and associated cancers.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Macrophages are key innate immune cells.
  • CD47 acts as a "don't eat me" signal, preventing phagocytosis by macrophages.
  • Tumor cells and SARS-CoV-2 infected cells overexpress CD47 to evade immune surveillance.

Purpose of the Study:

  • To explore the CD47 signaling pathway as a therapeutic target.
  • To investigate the potential of CD47-based immunotherapy for COVID-19 and associated cancers.

Main Methods:

  • Review of existing research on CD47 blockade in cancer immunotherapy.
  • Analysis of CD47's role in SARS-CoV-2 infection and immune evasion.
  • Focus on macrophage-mediated immunotherapy and combination strategies.

Main Results:

  • CD47 blockade using monoclonal antibodies (mAbs) or fusion proteins shows promise in cancer research.
  • CD47 overexpression is a potential biomarker for immune evasion in both cancer and COVID-19.
  • Combining CD47-targeted therapies with macrophage activation may enhance immune responses.

Conclusions:

  • The CD47-SIRPα axis is a viable target for innate immunotherapy.
  • Targeting CD47 presents a novel therapeutic strategy for COVID-19-associated cancers.
  • Further research into CD47-based combination therapies is warranted for infectious diseases and cancer.
Keywords:
CD47Innate immunotherapyPhagocytosisSIRPα

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

439
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
419
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K